(Circulation. 1995;92:2488-2495.)
© 1995 American Heart Association, Inc.
Articles |
Natural History of Hypertrophic Cardiomyopathy
A Population-Based Study, 1976 Through 1990
From the Division of Cardiovascular Diseases (C.R.C., G.S.R.) and the Department of Health Sciences Research (K.R.B., L.J.M.), Mayo Clinic and Mayo Foundation, Rochester, Minn, and the Division of Cardiology, Georgetown University Medical Center (B.J.G.), Washington, DC.
Correspondence and reprint requests to Guy S. Reeder, MD, Division of Cardiovascular Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
Background Hypertrophic cardiomyopathy is a disease entity characterized by marked heterogeneity in morphology and natural history. Most of our knowledge of the natural history of this disorder derives from the study of hospital-based populations and is influenced by referral bias. Therefore, this population-based study was undertaken to examine the natural history of hypertrophic cardiomyopathy among unselected residents of Olmsted County, Minnesota.
Methods and Results Patients with hypertrophic cardiomyopathy, confirmed by echocardiography, were identified by use of the resources of the Rochester Epidemiology Project. Patients with the echocardiographic features of hypertrophic cardiomyopathy but with long-standing hypertension requiring drug therapy were categorized as having hypertensive hypertrophic cardiomyopathy. Baseline clinical details and follow-up events were obtained by retrospective chart review. Thirty-seven patients were diagnosed with hypertrophic cardiomyopathy and 24 with hypertensive hypertrophic cardiomyopathy. Eight additional patients were first diagnosed at autopsy. The mean age of the 37 patients with hypertrophic cardiomyopathy was 59±20 years (range, 1 week to 92 years); the mean ventricular septal thickness was 17.5±3 mm. Follow-up was obtained for a median of 7.7 years (range, 45 days to 17.2 years). The 1- and 5-year survival rates were 95% and 92%, respectively; these rates did not differ from those of an age- and sex-matched population (P=NS). The annual risk of cardiac death was 0.7%. The mean age of patients with hypertensive hypertrophic cardiomyopathy was 79±8 years (range, 62 to 91 years), and the mean ventricular septal thickness was 19±2.5 mm. Follow-up was obtained for a median of 2.8 years (range, 4 days to 16.7 years). The 1- and 5-year survival rates were 75% and 43%, respectively, which differed sharply from the expected rates of 94% and 70% (P=.0028). The annual risk of cardiac death was 5%. Atrial fibrillation and evidence for myocardial infarction on ECG, use of digoxin and diuretics, and a high New York Heart Association functional class at presentation were all associated with decreased survival by multivariate analysis for both groups combined. A history of myocardial infarction, atrial fibrillation, and mitral annular calcification at presentation were associated with cardiac death.
Conclusions Hypertrophic cardiomyopathy is a more benign disease than previously reported from tertiary referral centers. Patients assessed as having hypertensive hypertrophic cardiomyopathy represent a subset at higher risk for cardiac and noncardiac death, with an overall decreased survival rate.
Key Words: cardiomyopathy • prognosis • follow-up studies
This article has been cited by other articles:
 |
|
 |
|
  O. Bruder, S. Schneider, D. Nothnagel, T. Dill, V. Hombach, J. Schulz-Menger, E. Nagel, M. Lombardi, A. C. van Rossum, A. Wagner, et al. EuroCMR (European Cardiovascular Magnetic Resonance) Registry: Results of the German Pilot Phase J. Am. Coll. Cardiol., October 6, 2009; 54(15): 1457 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sorajja, R. A. Nishimura, B. J. Gersh, J. A. Dearani, D. O. Hodge, H. J. Wiste, and S. R. Ommen Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. J. Am. Coll. Cardiol., July 14, 2009; 54(3): 234 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Elliott and P Spirito Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice Heart, October 1, 2008; 94(10): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Colan, S. E. Lipshultz, A. M. Lowe, L. A. Sleeper, J. Messere, G. F. Cox, P. R. Lurie, E. J. Orav, and J. A. Towbin Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry Circulation, February 13, 2007; 115(6): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-E. W. Kavey, V. Allada, S. R. Daniels, L. L. Hayman, B. W. McCrindle, J. W. Newburger, R. S. Parekh, and J. Steinberger Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics Circulation, December 12, 2006; 114(24): 2710 - 2738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Lekanne Deprez, J J Muurling-Vlietman, J Hruda, M J H Baars, L C D Wijnaendts, I Stolte-Dijkstra, M Alders, and J M van Hagen Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene J. Med. Genet., October 1, 2006; 43(10): 829 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
|
|
|
|
P M Elliott, J R Gimeno, R Thaman, J Shah, D Ward, S Dickie, M T Tome Esteban, and W J McKenna Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy Heart, June 1, 2006; 92(6): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Arad, M. Penas-Lado, L. Monserrat, B. J. Maron, M. Sherrid, C. Y. Ho, S. Barr, A. Karim, T. M. Olson, M. Kamisago, et al. Gene Mutations in Apical Hypertrophic Cardiomyopathy Circulation, November 1, 2005; 112(18): 2805 - 2811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Nugent, P. E.F. Daubeney, P. Chondros, J. B. Carlin, S. D. Colan, M. Cheung, A. M. Davis, C.W. Chow, R. G. Weintraub, and for the National Australian Childhood Cardiomyopat Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study Circulation, August 30, 2005; 112(9): 1332 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Olivotto, M. S. Maron, A. S. Adabag, S. A. Casey, D. Vargiu, M. S. Link, J. E. Udelson, F. Cecchi, and B. J. Maron Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol., August 2, 2005; 46(3): 480 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Isobe, H. Izawa, M. Iwase, M. Nanasato, M. Nonokawa, A. Ando, S. Ohshima, K. Nagata, K. Kato, T. Nishizawa, et al. Cardiac 123I-MIBG Reflects Left Ventricular Functional Reserve in Patients with Nonobstructive Hypertrophic Cardiomyopathy J. Nucl. Med., June 1, 2005; 46(6): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, S. A. Casey, R. G. Hauser, and D. M. Aeppli Clinical course of hypertrophiccardiomyopathy with survival to advanced age J. Am. Coll. Cardiol., September 3, 2003; 42(5): 882 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. C. Moon, W. J. McKenna, J. A. McCrohon, P. M. Elliott, G. C. Smith, and D. J. Pennell Toward clinical risk assessment inhypertrophic cardiomyopathy withgadolinium cardiovascular magnetic resonance J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1561 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, L. A. Sleeper, J. A. Towbin, A. M. Lowe, E. J. Orav, G. F. Cox, P. R. Lurie, K. L. McCoy, M. A. McDonald, J. E. Messere, et al. The Incidence of Pediatric Cardiomyopathy in Two Regions of the United States N. Engl. J. Med., April 24, 2003; 348(17): 1647 - 1655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. M. Kofflard, F. J. Ten Cate, C. van der Lee, and R. T. van Domburg Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration J. Am. Coll. Cardiol., March 19, 2003; 41(6): 987 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Marian On predictors of sudden cardiac death in hypertrophic cardiomyopathy J. Am. Coll. Cardiol., March 19, 2003; 41(6): 994 - 996. [Full Text] [PDF]
|
|
|
|
|
|
L. Choudhury, H. Mahrholdt, A. Wagner, K. M. Choi, M. D. Elliott, F. J. Klocke, R. O. Bonow, R. M. Judd, and R. J. Kim Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2156 - 2164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maron Hypertrophic Cardiomyopathy: A Systematic Review JAMA, March 13, 2002; 287(10): 1308 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Eriksson, B. Sonnenberg, A. Woo, P. Rakowski, T. G. Parker, E. D. Wigle, and H. Rakowski Long-term outcome in patients with apical hypertrophic cardiomyopathy J. Am. Coll. Cardiol., February 20, 2002; 39(4): 638 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Miura, H Nakagawa, Y Morikawa, S Sasayama, A Matsumori, K Hasegawa, Y Ohno, A Tamakoshi, T Kawamura, and Y Inaba Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey Heart, February 1, 2002; 87(2): 126 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Elliott, J. Poloniecki, S. Dickie, S. Sharma, L. Monserrat, A. Varnava, N. G. Mahon, and W. J. McKenna Sudden death in hypertrophic cardiomyopathy: identification of high risk patients J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2212 - 2218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, I. Olivotto, P. Spirito, S. A. Casey, P. Bellone, T. E. Gohman, K. J. Graham, D. A. Burton, and F. Cecchi Epidemiology of Hypertrophic Cardiomyopathy-Related Death : Revisited in a Large Non-Referral-Based Patient Population Circulation, August 22, 2000; 102(8): 858 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Olivotto, B. J. Maron, A. Montereggi, F. Mazzuoli, A. Dolara, and F. Cecchi Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., June 1, 1999; 33(7): 2044 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, R. Mathenge, S. A. Casey, L. C. Poliac, and T. F. Longe Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1590 - 1595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Elliott, S. Sharma, A. Varnava, J. Poloniecki, E. Rowland, and W. J. McKenna Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., May 1, 1999; 33(6): 1596 - 1601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, S. A. Casey, L. C. Poliac, T. E. Gohman, A. K. Almquist, and D. M. Aeppli Clinical Course of Hypertrophic Cardiomyopathy in a Regional United States Cohort JAMA, February 17, 1999; 281(7): 650 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Takagi, T. Yamakado, and T. Nakano Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., January 1, 1999; 33(1): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Spirito, C. E. Seidman, W. J. McKenna, and B. J. Maron The Management of Hypertrophic Cardiomyopathy N. Engl. J. Med., March 13, 1997; 336(11): 775 - 785. [Full Text] [PDF]
|
|